Navigation Links
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
Date:5/29/2012

RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.(1)

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of linagliptin and metformin. If approved by the European Commission, JENTADUETO will provide a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.(2)

"The CHMP positive opinion for JENTADUETO marks another important regulatory milestone for the Boehringer Ingelheim and Eli Lilly and Company worldwide diabetes alliance, extending our commitment to bringing new medicines to those patients who need them," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "Around the world, many people with type 2 diabetes require more than one treatment to adequately manage their blood sugar. By combining two important diabetes medicines in a single tablet, we believe that JENTADUETO will provide people with type 2 diabetes another way of improving control of their blood sugar."

JENTADUETO was approved by the U.S. Food and Drug Administration (FDA) in January 2012 as a prescription medicine used along with diet and exercise to improve glycemic control i
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
2. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
3. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
4. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
7. Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
8. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
11. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
(Date:9/2/2014)... 2014    - Los ... agentes antitrombóticos no utilizados óptimamente para prevenir la ... presentaciones de GARFIELD-AF en el ESC CONGRESS 2014 ... resultados de pacientes en riesgo de sufrir apoplejía ... Los datos de casi 12.500 pacientes reclutados ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:9/2/2014)... After respective performances in the 2014 World Cup, Brazil and ... Sun Life Stadium. The World Cup allowed the world to ... in Colombian and Brazilian stars. Diehard soccer fans in Miami will ... in early September. , Brazil is currently ranked as the 7th ... nation of the 2014 World Cup was originally favored to win ...
(Date:9/2/2014)... Recently, iFitDress.com, a famous online supplier of ... its range of 2014 seashell wedding dresses . ... prices. A large proportion of them are priced under ... are carefully made by the most skilled workers. Along ... gowns, ivory satin wedding gowns, white halter wedding gowns, ...
(Date:9/2/2014)... 2, 2014 4 pm EDT): In a Viewpoint published ... Association , a team of Boston researchers call for ... quality in the United States. The researchers from the ... University, Harvard University and Boston Children,s Hospital write that ... foods could both help people make meaningful dietary changes ...
(Date:9/2/2014)... The exciting information sessions and AMTC auditions will ... and Bob Wiley. The team of scouts prayerfully ... desire to illuminate entertainment with the light of Christ. ... to join the Bridge Training Program and ... 6, Charlotte Convention Center, 501 South College St., Charlotte, ...
(Date:9/2/2014)... Friendship Village of Schaumburg is ... creates a contemporary marketing presence and visually solidifies ... organization, Friendship Senior Options,” said Stephen A. Yenchek, ... changing the logo, we are making sure that ... and their families.” , Friendship Village is a ...
Breaking Medicine News(10 mins):Health News:Brazil Vs. Colombia Tickets in Miami at Sun Life Stadium: Dazzling Deals Tickets Advises Soccer Fans To Reserve Tickets Early for Brazil vs. Colombia Rematch in Florida 2Health News:Brazil Vs. Colombia Tickets in Miami at Sun Life Stadium: Dazzling Deals Tickets Advises Soccer Fans To Reserve Tickets Early for Brazil vs. Colombia Rematch in Florida 3Health News:Discounted Seashell Wedding Dresses Currently Provided By iFitDress.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2
... According to it, the packaging or covering on the ... they claim to be able to cure. ... area of licensed medicines, the National Rules System was ... no scientific proof to confirm their claims will be ...
... study by the UC Davis researchers states that children from ... choosing better after school snacks. // ,The study by ... September issue of the American Journal of Public Health, has ... the vending machines aren't the only places that need to ...
... an increased risk of developing lymphoma and leukemia. The ... pain does have the risk of cancer. //Researchers speculate ... alpha (TNFá) antagonists, a type of biologic DMARD may ... which work by attaching to and impeding chemical messengers ...
... and vegetable juices may have the unique property or reducing the ... examined more than 2,000 people in the study, which appears in ... ,The researchers found that the risk of Alzheimer's was reduced by ... least three times a week as compared to those who drank ...
... past decade saw a decrease in traumatic head injuries ... according to a new report released on Wednesday.// ... hospital admissions for traumatic head injuries from 1994 to ... 35 per cent since 1994, with children and youth ...
... Research Institute are optimistic about a visual device that may ... , ,During a study to gauge the ... was a marked increase in the way the visually impaired ... which comprises of a small camera, pocket-sized computer and see-through ...
Cached Medicine News:Health News:Doctors worried about Homeopathic licensing 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 3Health News:RA Drugs Not Implicated In Cancer 2
... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... of the MYOHANDY family are probably ... MYOQUICK - SystemPLUS line. Based on ... systems of the ISA 100x EP ... ISA 1002 EP) , 4 channels ...
Medicine Products: